

**Cadila Healthcare Ltd. - Consolidated
Break-up of Gross Sales**

Rs. Mio.

Rs. Mio.	Q1 10-11	Q1 09-10	% Gr y-y
Domestic	5,675	4,758	19.3%
Formulations	4,361	3,719	17.3%
Branded Formulations	4,142	3,534	17.2%
Generic Formulations	219	185	18.4%
API	92	82	12.2%
Consumer & Others	1,222	957	27.7%
Consumer Products	873	642	36.1%
Animal Health & Others	349	316	10.6%
Exports	5,007	4,138	21.0%
Formulations	3,952	3,327	18.8%
North America	2,227	1,479	50.6%
Europe	632	638	-0.9%
Latin America	387	366	5.9%
Japan	89	84	6.4%
Emerging Markets	476	527	-9.5%
Zydus Hospira (50%)	139	234	-40.5%
API	1,055	811	30.1%
Zydus Nycomed (50%)	153	294	-47.8%
Others	902	517	74.5%
Total	10,682	8,896	20.1%

**Cadila Healthcare Ltd. - Consolidated
Other Details pertaining to Q1 10-11**

Rs. Mio.

R&D Expenses	Q1 10-11	Q1 09-10	% Gr y-y
R&D Revenue Expenses	585	469	24.7%
R&D Capex	84		

Other Incomes	Q1 10-11	Q1 09-10	% Gr y-y
A. Operating Income			
a. Export Incentive	26	25	4.0%
b. Processing Income	78	104	-25.0%
c. Royalty Income	77	63	22.2%
d. Exchange Rate Fluctuations	73		
e. Dossier License Fees from Abbott	474		
f. Others	59	40	47.5%
Total Operating Income	787	232	239.2%
B. Other Income			
a. Interest Income	29	39	-25.6%
b. Rent received		3	
Total Other Income	29	42	-31.0%

Consolidated Capex for Q1 10-11 (Excl. Goodwill)	Rs. 594 Mio.
---	-------------------------